Biosig Technologies (BSGM) Stock Price, News & Analysis

Company Overview

Biosig Technologies, Inc. is a clinical-stage medical device company developing advanced signal acquisition and processing systems for interventional electrophysiology. Its lead product, the PURE EP™ System, is designed to enhance the quality and reliability of intracardiac recordings during diagnostic and therapeutic procedures for cardiac arrhythmias, including atrial fibrillation and other rhythm disorders.

The PURE EP™ System integrates proprietary hardware and software to deliver higher-fidelity electrograms, helping physicians distinguish true cardiac signals from noise. Biosig Technologies is collaborating with electrophysiology labs and research institutions across the United States to conduct clinical studies and support regulatory filings aimed at expanding market access for its platform.

Founded in the early 2010s and headquartered in New York, Biosig Technologies has pursued U.S. Food and Drug Administration (FDA) regulatory clearance for its flagship device and initiated preparations for European CE mark registration. The company’s pipeline also includes software upgrades and ancillary tools intended to further improve procedural workflows and patient outcomes.

Under the leadership of President and Chief Executive Officer Kenneth L. Londoner, Biosig Technologies is positioning its PURE EP™ platform to address unmet needs in the growing field of cardiac rhythm management. By offering enhanced signal clarity and analytic capabilities, the company aims to become a preferred partner for electrophysiologists seeking innovative technologies to optimize interventional procedures.

Key Stats

• Today's Range: N/A
• 50-Day Range: $3.68 to $6.35
• 52-Week Range: N/A
• Volume: 3.10 million shs
• Average Volume: 918,255 shs
• Market Capitalization: $199.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Biosig Technologies Stock Analysis - MarketRank™

Biosig Technologies scored higher than 34% of companies evaluated by MarketBeat, and ranked 753rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biosig Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Biosig Technologies has a consensus price target of $10.00, representing about ∞ upside from its current price of $0.00.

Amount of Analyst Coverage

Biosig Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biosig Technologies are expected to grow in the coming year, from ($0.88) to ($0.73) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BSGM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biosig Technologies does not currently pay a dividend.

Dividend Growth

Biosig Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BSGM.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for BSGM on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Biosig Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biosig Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.80% of the stock of Biosig Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.16% of the stock of Biosig Technologies is held by institutions.

BSGM Stock Analysis - Frequently Asked Questions

How were Biosig Technologies' earnings last quarter?

Biosig Technologies, Inc. (NASDAQ:BSGM) posted its quarterly earnings data on Friday, August, 15th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.70.

When did Biosig Technologies' stock split?

Shares of Biosig Technologies reverse split on Friday, February 2nd 2024.The 1-10 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Biosig Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biosig Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Roku (ROKU) and Ford Motor (F).

Company Calendar

• Last Earnings: 8/15/2025
• Today: 10/20/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BSGM
• CIK: 1530766
• Web: www.biosig.com
• Phone: (230) 409-5444
• Fax: N/A
• Employees: 50
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Biosig Technologies: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.33 million
• Net Margins: N/A
• Pretax Margin: -201,392.33%
• Return on Equity: -5,336.99%
• Return on Assets: -90.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: $13 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 31,419,000
• Free Float: 23,627,000
• Market Cap: $199.35 million
• Optionable: No Data
• Beta: 1.82